Floating Button
Home News Healthcare

Hyphens Pharma enjoys lift from broader product range and wider distribution channels

Amala Balakrishner
Amala Balakrishner • 9 min read
Hyphens Pharma enjoys lift from broader product range and wider distribution channels
Hyphens’ CFO Fang Lee Wei sayS the counter was “under-recognised and severely undervalued” in its first 18 months since listing.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Over two years ago, on May 18, 2018, Hyphens Pharma International made its Catalist debut on the Singapore Exchange at 30 cents. In the subsequent 18 months, its share price barely moved a needle, leading CFO Fang Lee Wei to say the counter was “under-recognised and severely undervalued”.

“Even though retail investors may have been using our products, not many of them know our brand since Hyphens focuses mainly on business-to-business distribution,” she tells The Edge Singapore in a recent interview.

Things have been changing course for the pharmaceutical distributor which has been bringing the Hyphens brand to retail investors through roadshows, events and social media engagements. These have helped push the counter to gain some 8.5 cents or 28.8% to close at 38.5 cents on Sept 10. More recently, its share price has been on the uptrend, with a notable surge on July 15 when it finished at 48 cents, some 50% or 16 cents higher than the previous day’s 32-cent close. In the process, some 55.8 million shares changed hands.

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2026 The Edge Publishing Pte Ltd. All rights reserved.